Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 16;7(78):eadd3899. doi: 10.1126/sciimmunol.add3899

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1. — (A) Schematic depiction of the SARS-CoV-2 spike protein and protein section coverage by the peptide pools (Prot_S1, Prot_S+, and Prot_S) used for immunogenicity testing. (B to F) Ex vivo T cell responses after complete vaccination [two doses of BNT162b2, mRNA-1273, or ChAdOx1; one dose of Ad26.COV2.S; or one dose of the vector vaccine ChAdOx1 followed by one dose of an mRNA vaccine for heterologous (Heterol.) vaccine regimens] compared with COVID-19 convalescents (Conv.) and prepandemic (Pre.) donors were assessed by IFN-γ ELISpot assays 3 to 12 weeks (median, 4 weeks) after the last vaccine dose (sample collection after complete vaccination; Table 1). (B) Representative example of ex vivo IFN-γ T cell responses to the Prot_S1 peptide pool compared with a negative (neg.) control peptide showing duplicates for one donor of each cohort. (C and D) Percentage of individuals with ex vivo IFN-γ ELISpot T cell responses (C) and intensities of IFN-γ T cell responses in terms of calculated spot counts against the spike-specific peptide pools (D) after mRNA, vector, or heterologous vaccination compared with convalescents and prepandemic donors (summarized responses against the three spike-specific peptide pools). (E) Intensities of ex vivo IFN-γ T cell responses shown for the distinct spike protein peptide pools. (F) Proportion of individuals (cohorts as indicated by color code) with responses to all three, two, one, or none of the spike peptide pools. Responders are represented by colored symbols, and nonresponders are represented by clear symbols. Symbol shapes indicate the different vaccine products received by the donors. (D and E) Box plots represent the median with the 25th and 75th percentiles with minimum and maximum whiskers. (C) Fisher’s exact test was used. (D) Kruskal-Wallis test was used. (E) Friedman test was used. If P values are not shown, then results were not significant. RBD, receptor binding domain; No., number.